RegenETP, Inc. Share Price

Stocks

02/25/02	PolarityBio Announces Launch of Expanded Access Treatment Protocol to Provide Continued Access to SkinTE for Patients with Wagner 1 Diabetic Foot Ulcers	CI
26/25/26	PolarityBio Completes Enrollment in the Phase III Pivotal Study of SkinTE for Diabetic Foot Ulcers	CI
20/24/20	RegenETP, Inc. announced that it expects to receive $22.5 million in funding from Avenue Capital Group, LLC	CI
26/24/26	PolarityTE Screens First Subject in Phase III Pivotal Study Evaluating Investigational New Drug SkinTE® in Diabetic Foot Ulcers	CI
19/23/19	PolarityTE, Inc. Announces Resignation of Jacob Patterson as Chief Financial Officer	CI
19/23/19	PolarityTE, Inc. Announces Executive Changes	CI
18/23/18	PolarityTE, Inc. has Changed its Name to RegenETP, Inc	CI
15/23/15	Grander Acquisition LLC completed the acquisition of Substantially all of the assets of PolarityTE, Inc..	CI
01/23/01	PolarityTE, Inc. Announces the Resignation of Jeff Dyer from the Company's Board of Directors	CI
15/23/15	PolarityTE, Inc.(OTCPK:PTEI.Q) dropped from NASDAQ Composite Index	CI
13/23/13	PolarityTE, Inc.(NasdaqCM:PTE) dropped from S&P TMI Index	CI
07/23/07	Grander Acquisition LLC entered into a stalking horse asset purchase agreement to acquire Substantially all of the assets of PolarityTE, Inc. for $6.5 million.	CI
13/23/13	PolarityTE, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	CI

28/22/28	Northland Securities Adjusts Price Target on PolarityTE to $1 From $1.25, Maintains Outperform Rating	MT
31/22/31	Cantor Fitzgerald Downgrades PolarityTE to Neutral From Overweight, Adjusts Price Target to $1 From $2.50	MT

16/23/16	PolarityTE : Acquisition/Asset Disposal - Form 8-K	PU
08/23/08	POLARITYTE, INC. : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing (form 8-K)	AQ
07/23/07	POLARITYTE, INC. : Entry into a Material Definitive Agreement, Bankruptcy or Receivership, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)	AQ
27/23/27	POLARITYTE, INC. : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing (form 8-K)	AQ
28/23/28	POLARITYTE, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-K)	AQ

1 day

-8.24%

Manager	Title	Age	Since
Nikolai Sopko CTO	Chief Tech/Sci/R&D Officer	-	-
Ryan Mathis CTO	Chief Tech/Sci/R&D Officer	-	01/09/2021
Stephen Milner CTO	Chief Tech/Sci/R&D Officer	-	30/03/2017

Date	Insider	Type	Main position	Quantity	% Market Cap.
26/01/23	Jeffrey Dyer	Other	Director	11,872	0.1641%
26/01/23	Jeffrey Dyer	Free	Director	42,986	0.5942%
12/01/23	Christian Nolet	Exercice	Director	39,575	0.5470%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
REGENETP, INC.	-8.24%	+0.65%	-	-	11.22L
CHURCHILL CAPITAL CORP XI	+6.83%	+4.71%	-	-	72Cr
DRUGS MADE IN AMERICA ACQUISITION II CORP.	-0.05%	+0.07%	-	-	65Cr
CENTIEL AG	+2.91%	+9.28%	+299.50%	-73.72%	63Cr
BAIN CAPITAL GSS INVESTMENT CORP.	-0.10%	0.00%	-	-	60Cr
CHURCHILL CAPITAL CORP XII	-0.98%	-1.25%	-	-	59Cr
CANTOR EQUITY PARTNERS IV, INC.	-0.29%	-0.14%	+1.47%	-	59Cr
AMERICAN EXCEPTIONALISM ACQUISITION CORP. A	-0.36%	-1.68%	-	-	55Cr
NEW AMERICA ACQUISITION I CORP.	-0.18%	-0.44%	-	-	50Cr
Average	-0.05%	+1.32%	+150.48%	-73.72%	60.39Cr
Weighted average by Cap.	+1.16%	+1.51%	+155.29%	-73.72%